Sotera Health (SHC) PT Raised to $35 at Jefferies After Reporting its First Public Quarter
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
- J&J (JNJ) Privately Asked Rival Covid-19 Vaccine Makers to Inspect Clotting Risks, AstraZeneca (AZN) Said Yes but Pfizer (PFE) and Moderna (MRNA) Declined - Report
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Jefferies analyst David Windley raised the price target on Sotera Health (NASDAQ: SHC) to $35.00 (from $33.50) after the company made a clean break in its 1st public quarter.
The analyst reiterated the Buy rating, stating "We think trading weakness ahead of results reflected concern about 1Q COVID flare-ups stunting near-term growth and, perhaps, using up any conservatism in the IPO targets for FY21. That didn't happen. Both 1Q20 indicators and FY21 landed ahead of JEF/cons. We think pre-IPO FY21 segment growth rates remains directionally intact, just now a bit steeper and Nordion's cadence a bit smoother. Pricing remains SHC's key LT driver for both revs and margins, with L/MSD increases supported by contractual escalators, tight supply, and high switching costs for Sterigenics and Nordion. We see little risk to margins, barring further disruption to procedure vols as FY21 progresses."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Siemens AG (SIE:GR) (SIEGY) PT Raised to EUR170 at Jefferies
- Shinhan Financial Group (055550:KS) (SHG) PT Raised to KRW48,000 at Morgan Stanley
- KB Financial Group (105560:KS) (KB) PT Raised to KRW67,500 at Morgan Stanley
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Related EntitiesJefferies & Co, IPO
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!